290 related articles for article (PubMed ID: 34830289)
1. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice.
Huang CC; Chou CA; Chen WY; Yang JL; Lee WC; Chen JB; Lee CT; Li LC
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830289
[TBL] [Abstract][Full Text] [Related]
2. Palmitate aggravates proteinuria-induced cell death and inflammation via CD36-inflammasome axis in the proximal tubular cells of obese mice.
Li LC; Yang JL; Lee WC; Chen JB; Lee CT; Wang PW; Vaghese Z; Chen WY
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1720-F1731. PubMed ID: 30230367
[TBL] [Abstract][Full Text] [Related]
3. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
Chen Y; Li Y; Wang Y; Wen Y; Sun C
Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity.
Byun JH; Lebeau PF; Platko K; Carlisle RE; Faiyaz M; Chen J; MacDonald ME; Makda Y; Yousof T; Lynn EG; Dickhout JG; Krepinsky JC; Weaver F; Igdoura SA; Seidah NG; Austin RC
Kidney360; 2022 Aug; 3(8):1394-1410. PubMed ID: 36176646
[TBL] [Abstract][Full Text] [Related]
6. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-
Liu Y; Cheng F; Luo Y; Zhan Z; Hu P; Ren H; Tang H; Peng M
Biomed Res Int; 2017; 2017():8234507. PubMed ID: 28770225
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
[TBL] [Abstract][Full Text] [Related]
8. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
9. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
12. A role for tubular Na
Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
[TBL] [Abstract][Full Text] [Related]
13. Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway.
Ahn JS; Yang JW; Oh SJ; Shin YY; Kang MJ; Park HR; Seo Y; Kim HS
BMB Rep; 2021 Jun; 54(6):323-328. PubMed ID: 34078528
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice.
Yang P; Xiao Y; Luo X; Zhao Y; Zhao L; Wang Y; Wu T; Wei L; Chen Y
J Lipid Res; 2017 Jul; 58(7):1417-1427. PubMed ID: 28536108
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
17. Mangiferin Improved Palmitate-Induced-Insulin Resistance by Promoting Free Fatty Acid Metabolism in HepG2 and C2C12 Cells via PPAR
Zhang Q; Kong X; Yuan H; Guan H; Li Y; Niu Y
J Diabetes Res; 2019; 2019():2052675. PubMed ID: 30809553
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
Ala M; Khoshdel MRF; Dehpour AR
Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease.
Hajri T; Zaiou M; Fungwe TV; Ouguerram K; Besong S
Cells; 2021 May; 10(6):. PubMed ID: 34072832
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
